Tiloron - instructions for use, dose, side effects, contraindications

Enhances the synthesis of endogenous α-, β- and γ-interferons in intestinal epithelial cells, hepatocytes, neutrophils and T-lymphocytes, has no antigenic activity, does not cause hyperinterferonemia. Affects stem cells of red bone marrow, increases the formation of antibodies, restores the proportion of T-helpers / T-suppressors, reducing the degree of immunosuppression.

Inhibits the transmission of virus-specific proteins in infected cells, stopping the reproduction of viruses. It is active against various viral infections, including hepatitis, herpes, and influenza.

Pharmacokinetics:

After ingestion after meals, up to 60% is absorbed in the gastrointestinal tract. The connection with plasma proteins is 80%.

It is not metabolized or cumulated.

The half-life period is 48 hours. Elimination with feces (70%) and kidneys (30%).

Indications:

It is used for the treatment of viral hepatitis A, B, C, herpetic and cytomegalovirus infection, it is used in the complex therapy of viral encephalitis, respiratory and urogenital chlamydiosis, is used for the prevention and treatment of influenza and acute respiratory viral infections.

ICD-10

I.A50-A64.A56.0 Chlamydial infections of the lower parts of the genito-urinary tract

I.A50-A64.A56.1 Chlamydial infections of the pelvic organs and other urogenital organs

I.A50-A64.A56.4 Chlamydial pharyngitis

I.A50-A64.A60 Anogenital herpetic viral infection [herpes simplex]

I.B00-B09.B00 Infections caused by the herpes simplex virus [herpes simplex]

I.B00-B09.B01 Chicken Pox [varicella]

I.B00-B09.B02.9 Shingles without complications

I.B15-B19.B17.1 Acute hepatitis C

I.B15-B19.B16 Acute hepatitis B

I.B15-B19.B15 Acute hepatitis A

I.B15-B19.B18.2 Chronic viral hepatitis C

I.B15-B19.B18.1 Chronic viral hepatitis B without delta-agent

I.B25-B34.B25 Cytomegalovirus

VI.G35-G37.G35 Multiple sclerosis

X.J00-J06.J06.9 Acute upper respiratory tract infection, unspecified

X.J10-J18.J11 Influenza, virus not identified

Contraindications:

Individual intolerance.

Carefully:

Severe kidney failure.

Pregnancy and lactation:

Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

Dosing and Administration:

Inside after a meal, for the purpose of prevention: 0,125 mg (1 tablet) 1 time / week for 4-6 weeks.

The standard treatment regimen is: inside after eating, 0.125-0.250 mg (1-2 tablets) per day for 2 days, then 1 tablet every 48 hours for 1-4 weeks. depending on the severity of the disease.

The highest daily dose: 0.250 (2 tablets).

The highest single dose: 0,125 (1 tablet).

Side effects:

Short-term chills, rarely - dyspepsia.

Allergic reactions.

Overdose:

Cases of overdose are not described.

Treatment is symptomatic.

Interaction:

Compatible with the drugs of all groups.

Special instructions:

When taken in doses exceeding therapeutic, the development of a short-term depletion of immunocompetent cells is possible.

Instructions

Tyloron (Tiloronum)